Compile Data Set for Download or QSAR
Report error Found 18 Enz. Inhib. hit(s) with all data for entry = 6692
TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM147463(US8957103, D)
Affinity DataIC50: 12nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47167(CHEMBL201511 | US8957103, Z1 | US9364459, A)
Affinity DataIC50: 90nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM147461(US8957103, C)
Affinity DataIC50: 134nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50: 153nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47163(US8957103, A)
Affinity DataIC50: 208nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM147463(US8957103, D)
Affinity DataIC50: 239nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM147463(US8957103, D)
Affinity DataIC50: 251nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47167(CHEMBL201511 | US8957103, Z1 | US9364459, A)
Affinity DataIC50: 270nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM147461(US8957103, C)
Affinity DataIC50: 480nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50: 554nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50: 556nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50: 920nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM147461(US8957103, C)
Affinity DataIC50: 1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47163(US8957103, A)
Affinity DataIC50: 1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47163(US8957103, A)
Affinity DataIC50: 1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47167(CHEMBL201511 | US8957103, Z1 | US9364459, A)
Affinity DataIC50: 1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50: 2.25E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50: 3.39E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/15/2015
Entry Details
Go to US Patent